This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Generex Comments On Results Of Stockholders` Meeting

WORCESTER, Mass. and TORONTO, April 3, 2013 /PRNewswire/ -- Generex Biotechnology Corporation ( (OTCBB: GNBT) today commented on the results of the meeting of the Company`s stockholders held on March 28, 2013.  On April 1, 2013, the Company filed a Form 8-K Current Report with the United States Securities and Exchange Commission detailing the voting results in respect of each of the proposals put forward at the meeting.  That report is publicly available in the online EDGAR database at

The slate of directors put forward in the Company`s proxy statement in respect of the meeting was elected:  John P. Barratt (Chairman of the Board); Brian T. McGee (Chairman of the Audit Committee of the Board of Directors); Dr. James H. Anderson, MD (Chief Scientific Advisor); Dr. Eric von Hofe, PhD (President of Antigen Express, Inc.); and, Mark A. Fletcher (President & Chief Executive Officer).

The proposals to (a) amend the Company`s Restated Certificate of Incorporation to increase the number of shares of common stock authorized thereunder, and (b) authorize the Board to effect a reverse stock split of the Company`s common stock (up until September 27, 2014), were approved by holders of a majority of the Company`s outstanding stock.  The proposal to amend the Company`s stock plan by increasing the number of shares of common stock available thereunder was also approved by the Company`s stockholders.

"We very much appreciate the support and confidence of our stockholders," Mr. Fletcher commented.  "These adjustments to the Generex capital structure will set the stage for the next phase in the life of Generex.  The approval of an increase in authorized capital permits Generex to continue to access the capital markets for the funding necessary to carry on our work.  The approval of a reverse stock split affords the Board flexibility in managing the Company`s capital structure for the benefit of their fellow stockholders.  The amendment of the stock plan will facilitate the retention and engagement of employees and consultants who will play a vital role in the future successes of Generex and Antigen Express.  These initiatives, as a package, will provide a solid foundation upon which our future successes can be securely built."

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs